For instance, in May of 2020, Central Admixture Pharmacy Services, Inc. announced three novel compounded sterile medicines, all of which are currently in low supply for intensive care unit (ICU) patients. The medications are two vasodilators, namely: In addition, 8 milligrams of norepinephrine, 50 units of vasopressin, and 125 milligrams of midazolam were mixed into normal saline at a concentration of 1 milligram per milliliter.In addition, West Pharmaceuticals Services, Inc., a 503B outsourcing facility, released its Ready Pack containment system in November 2019. This system is comprised of sterile, ready-to-use (RU) NovaPure stoppers, Daikyo Crystal Zenith cyclic olefin polymer vials, and Flip-Off (clean, certified, sterilized) CCS seals.
The U.S 503B Compounding Pharmacies Market is estimated to be valued at US$ 985.6 million in 2022 and is expected to exhibit a CAGR of 7.6 % over the forecast period (2022-2030)
Major Players in the U.S. 503B Compounding Pharmacies Industry:
1. Central Admixture Pharmacy Services, Inc
Central Admixture Pharmacy Services, Inc in 1991 and it’s Pennsylvania, 18106, United States. The company operates in 66 countries. In 2021 increasing launches of 503B compounding pharmacies in the U.S and ... Central Admixture Pharmacy Services, Inc.
2. Nephron Pharmaceuticals Corporation
Nephron Pharmaceuticals Corporation, founded in 1997, and its Headquarters located in Columbia, SC.. The company operates in 140 nations.
